Investing.com - TD Cowen initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with a Buy rating on Wednesday, citing the potential of the company’s telitacicept therapy. The stock, currently trading ...
Optical remote sensing technologies provide the ability to monitor short- and long-term changes in coral reefs, deep-sea fisheries, and off-shore oilfields, and to supply real-time information about ...
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the ...
Hosted on MSN
Trying a VOR Instrument Approach!
I love being a licensed private pilot. As you may have seen from other videos, I am starting my instrument rating training. I really believe that I will be a much safer pilot when I get my IFR or ...
While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition. Vor hit reset in May, after nearly a decade of work on blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results